|
||
| |||||||
Brussels - Paris, September 23rd 2005 – Privately held DNAVision and RNTECH announced today that the two companies had signed a co-marketing agreement, under which the companies will jointly offer an integrated package of high quality material biological bank, gene expression and genotyping technologies. Post-genome era discovery processes must be based upon the combination of two key components: high quality, severely selected biological material associated with diagnostic and clinical data from large scale patient cohorts and state of the art technology platforms including genomics, proteomics and bioinformatics platforms. The RNTECH/DNAVision offer associates these key components, creating an unique opportunity for pharmaceutical and biotechnology industries to access discovery and development expertise at an unparalleled level in oncology for biomarker and drugable target discovery and development. "We are delighted to combine our complete biological material bank in oncology with DNAVision’s gene expression and high-throughput genotyping platforms and offer, what we believe, a unique pharmacogenomic solution to pharmaceutical, clinical, and academic partners interested by finding new biomarkers in oncology" said Michaël Bia, CEO of RNTECH. “We believe that the quality of RNTECH’s biobank with complete clinical data and patient follow-up will provide in combination with our expertise a stronger, more clinically relevant offering for the oncology marketplace." said Jean-Pol Detiffe, CEO of DNAVision. About DNAVision Based in Belgium, DNAVision is a leading provider of applied pharmacogenetic & pharmacogenomic services. DNAVision offers the powerful combination of different technologies in expression profiling, SNP genotyping and sequencing in a high quality environment. DNAVision is a spin-off of BioVallée, University of Brussels and Institute of Pathology and Genetics. More information on DNAVision service portfolio can be found on www.dnavision.be About RNTECH Based in France, RNTECH SAS is a biotech developing company incorporated in March 2002 and a leading biotechnology company in the field of early stage digestive tract cancer diagnostic tools and treatment discovery and development. This leadership is made possible based upon an exclusive access to high standard biological material and data combined with original discovery processes and state of the art technology. www.rntech.com Further information: Jean-Pol Detiffe Michaël Bia DNAVision RNTECH Tel. +32 71 378 527 Tel. +33 1 40071121 Fax. +32 71 378 501 Fax. +33 1 40071094 jp.detiffe@dnavision.be mbia@rntech.com www.dnavision.be www.rntech.com
|
| |||||||||||
| ||||||||
